Enjaymo
Enjaymo is a lab-made antibody that helps prevent the destruction of red blood cells in people with a rare blood condition known as cold agglutinin disease.
Approved in February 2022, the annual cost of the drug is expected to be around $280,000, according to a report from Reuters. Enjaymo isn’t alone in its excessiveness either, as the median annual cost of newly launched drugs in 2022 so far is around $257,000.
